Summary:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 28- Day Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of NST-1024 400 mg BID versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects (Study of the Efficacy and Safety of NST-1024 versus Placebo in Subjects with Hypertriglyceridemia)
Qualified Participants Must:
• Be 18 - 79 years old
• Have triglyceride levels of 500&ndash
•2,000 mg/dL
• Be on a statin or non-statin lipid lowering therapy (i.e. ezetimine, niacin, bempedoic acide, fibrates, etc.)
• Additional criteria apply
Qualified Participants May Receive:
Up to $1,225–$1,375 for time and travel